Working with the institutional review board
Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed. The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principle...
Saved in:
Published in | American journal of health-system pharmacy Vol. 66; no. 2; pp. 176 - 184 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
England
American Society of Health-System Pharmacists
15.01.2009
Oxford University Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed.
The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review.
IRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process. |
---|---|
AbstractList | Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed.
The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review.
IRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process. Purpose. Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed. Summary. The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review. Conclusion. IRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process. Index terms: Clinical studies; Compliance; Ethics; Institutional review boards; Methodology Am J Health-Syst Pharm. 2009; 66:176-84 Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed.PURPOSEWorking with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed.The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review.SUMMARYThe Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review.IRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process.CONCLUSIONIRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process. |
Audience | Academic |
Author | Wesley G. Byerly |
Author_xml | – sequence: 1 givenname: Wesley G. surname: Byerly fullname: Byerly, Wesley G. organization: Duke University School of Medicine, Durham, NC 27708 |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19139484$$D View this record in MEDLINE/PubMed |
BookMark | eNptkEtLJDEURoMo43PjDxhq4yxGSm8encdSZEYFwY3iMqSqbnXFqUebpC389xNpR0GGLBLC-T7uPftke5xGJOSYwhmjQp67p24FCkDKLbJHF3xRMgOwnd-gTMlAs12yH-MTAGUa5DeySw3lRmixR04fp_DHj8ti9qkrUoeFH2PyaZ38NLq-CPjicS6qyYXmkOy0ro949H4fkIffv-4vr8vbu6uby4vbsuYLkUoFLTONVOgcY21lJErNK6mE05xRtaiMUJqDqQANRaq5roVqRGNaQx1nwA_Ij03vKkzPa4zJDj7W2PduxGkdrZSa5g1EBs824NL1aP3YTim4Op8GB19nSa3P_xcs702ZkjIHvr83r6sBG7sKfnDh1f7zkQHYAHWYYgzY2ton9-YiN_veUrBvyu2n8hz5-SXy0fo_-GQDd37ZzT6gjYPr-zwOs_M8S2mZpUryvwrGjEw |
CitedBy_id | crossref_primary_10_1177_1556264616631657 crossref_primary_10_3233_BMR_210153 crossref_primary_10_1080_08989621_2014_956866 crossref_primary_10_1007_s10877_014_9582_6 crossref_primary_10_1177_15562646211009680 crossref_primary_10_3928_00220124_20111101_03 crossref_primary_10_1016_j_outlook_2010_04_003 crossref_primary_10_1016_j_dental_2011_08_595 crossref_primary_10_1213_ANE_0b013e3181cc5727 crossref_primary_10_3390_s23115003 crossref_primary_10_5435_00124635_201306000_00006 crossref_primary_10_2146_ajhp120449 crossref_primary_10_2146_ajhp170183 crossref_primary_10_3999_jscpt_41_113 crossref_primary_10_1002_eahr_500202 crossref_primary_10_2146_ajhp120167 crossref_primary_10_3346_jkms_2023_38_e198 crossref_primary_10_1007_s40617_018_0206_3 crossref_primary_10_1097_NUR_0000000000000197 crossref_primary_10_1017_S1461145710001112 crossref_primary_10_3390_f13101625 crossref_primary_10_1002_wjs_12038 crossref_primary_10_1007_s40615_023_01800_5 crossref_primary_10_3928_00220124_20111101_64 crossref_primary_10_1002_aorn_13498 crossref_primary_10_1093_bja_aes298 crossref_primary_10_1310_hpj5202_105 |
Cites_doi | 10.1097/00019514-200610000-00003 10.1056/NEJM198707163170304 10.1016/j.jclinepi.2005.11.018 10.1001/jama.1996.03540200077043 10.1177/0894318405277534 10.1001/jama.283.17.2275 10.1378/chest.130.5.1605 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2009 Oxford University Press |
Copyright_xml | – notice: COPYRIGHT 2009 Oxford University Press |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.2146/ajhp070066 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1535-2900 |
EndPage | 184 |
ExternalDocumentID | A201212766 19139484 10_2146_ajhp070066 www66_2_176 |
Genre | Journal Article Review |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GroupedDBID | - 04C 0R 23M 4.4 48X 53G 5GY 5RE 5RS 5WD AABJS AABMN AAIMJ AALRV AAPBV AAPQZ AAWTL AAYEP ABDBF ABFLS ABPTK ACDCL ACIMA ACIWK ACPRK ADBBV ADEIU ADGZP ADIPN ADRTK AELNO AELWJ AENEX AETBJ AFRAH AGINJ AGVJH AIKOY AIMBJ ALMA_UNASSIGNED_HOLDINGS BCRHZ BEYMZ CS3 EAD EAP EAS EBC EBD EBS ECF ECT ECV EHN EJD EMB EMK ENC ENERS EPL EPT EST ESX EX3 F5P FH7 FHSFR FOTVD FQBLK GAUVT H13 IAO IHR INH INR ITC J5H KBUDW KOP KSN L7B M5 MHKGH MV1 NLBLG NOYVH NVLIB O9- OB4 OBOKY OCZFY ODMLO OVD OWPYF P2P Q~Q R0Z RHI ROX RZL SJN SV3 TSH TUS WH7 WOW XZ YCJ YXANX --- .XZ 08P 0R~ 1CY 36B 6J9 6PF AABZA AACZT AAPXW AARHZ AAUAY AAVAP AAYOK AAYXX ABCQX ABDFA ABEJV ABGNP ABJNI ABMNT ABNHQ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ABXZS ACFRR ACGFO ACUHS ACUTJ ACYHN ADGKP ADNBA ADOJX ADQBN ADVEK AEGXH AEMQT AFFZL AFGWE AFXAL AGORE AGQXC AGUTN AHMMS AIAGR AJEEA AJNCP ALXQX ATGXG BMSDO C45 CITATION EIHBH EMOBN FECEO FLUFQ FOEOM JXSIZ KSI M5~ MK0 NOMLY OAUYM OFXIZ OJZSN OPAEJ OVIDX PONUX RUSNO TEORI TMA VVN WQ9 YFH YOC CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c354t-70f29d67eaa22fb96e683b674a832175b9478309b0e91e1838c47d4d9f91a3203 |
ISSN | 1079-2082 1535-2900 |
IngestDate | Tue Aug 05 09:46:43 EDT 2025 Tue Jun 10 21:24:19 EDT 2025 Wed Feb 19 02:33:40 EST 2025 Tue Jul 01 02:55:54 EDT 2025 Thu Apr 24 22:58:21 EDT 2025 Tue Jan 05 20:16:59 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c354t-70f29d67eaa22fb96e683b674a832175b9478309b0e91e1838c47d4d9f91a3203 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
PMID | 19139484 |
PQID | 66811914 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_66811914 gale_infotracacademiconefile_A201212766 pubmed_primary_19139484 crossref_citationtrail_10_2146_ajhp070066 crossref_primary_10_2146_ajhp070066 highwire_smallpub2_www66_2_176 |
ProviderPackageCode | RHI CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20090115 2009-01-15 2009-Jan-15 |
PublicationDateYYYYMMDD | 2009-01-15 |
PublicationDate_xml | – month: 01 year: 2009 text: 20090115 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | American journal of health-system pharmacy |
PublicationTitleAlternate | Am J Health Syst Pharm |
PublicationYear | 2009 |
Publisher | American Society of Health-System Pharmacists Oxford University Press |
Publisher_xml | – name: American Society of Health-System Pharmacists – name: Oxford University Press |
References | ( key 2019041002323634100_R1) 1996; 276 ( key 2019041002323634100_R13) 2000; 283 ( key 2019041002323634100_R14) 2001; 36 ( key 2019041002323634100_R11) 2006 ( key 2019041002323634100_R18) 1987; 317 ( key 2019041002323634100_R21) 2007 ( key 2019041002323634100_R17) 2005; 18 ( key 2019041002323634100_R24) 2007 ( key 2019041002323634100_R4) 2007 ( key 2019041002323634100_R5) 1986 ( key 2019041002323634100_R15) 2006; 15 ( key 2019041002323634100_R9) 2006 ( key 2019041002323634100_R12) 2007 ( key 2019041002323634100_R22) 2007 ( key 2019041002323634100_R16) 2006; 130 ( key 2019041002323634100_R6) 1982 ( key 2019041002323634100_R7) 2007 ( key 2019041002323634100_R2) 2007 ( key 2019041002323634100_R3) 2007 ( key 2019041002323634100_R25) 2007 ( key 2019041002323634100_R8) 2007 ( key 2019041002323634100_R20) 2007 ( key 2019041002323634100_R23) 2007 ( key 2019041002323634100_R10) 2006 ( key 2019041002323634100_R19) 2006; 59 |
References_xml | – year: 2006 ident: key 2019041002323634100_R10 – year: 2007 ident: key 2019041002323634100_R4 – volume: 15 start-page: 215 year: 2006 ident: key 2019041002323634100_R15 publication-title: Qual Manag Health Care doi: 10.1097/00019514-200610000-00003 – year: 2007 ident: key 2019041002323634100_R21 – year: 2007 ident: key 2019041002323634100_R25 – year: 1982 ident: key 2019041002323634100_R6 – year: 2007 ident: key 2019041002323634100_R12 – volume: 317 start-page: 141 year: 1987 ident: key 2019041002323634100_R18 publication-title: N Engl J Med doi: 10.1056/NEJM198707163170304 – year: 2007 ident: key 2019041002323634100_R20 – volume: 59 start-page: 784 year: 2006 ident: key 2019041002323634100_R19 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2005.11.018 – year: 2007 ident: key 2019041002323634100_R22 – year: 2006 ident: key 2019041002323634100_R11 – year: 2007 ident: key 2019041002323634100_R8 – year: 2006 ident: key 2019041002323634100_R9 – year: 1986 ident: key 2019041002323634100_R5 – year: 2007 ident: key 2019041002323634100_R23 – year: 2007 ident: key 2019041002323634100_R7 – volume: 276 start-page: 1691 year: 1996 ident: key 2019041002323634100_R1 publication-title: JAMA doi: 10.1001/jama.1996.03540200077043 – volume: 36 start-page: 213 year: 2001 ident: key 2019041002323634100_R14 publication-title: Formulary – volume: 18 start-page: 264 year: 2005 ident: key 2019041002323634100_R17 publication-title: Nurs Sci Q doi: 10.1177/0894318405277534 – year: 2007 ident: key 2019041002323634100_R3 – volume: 283 start-page: 2275 year: 2000 ident: key 2019041002323634100_R13 publication-title: JAMA doi: 10.1001/jama.283.17.2275 – volume: 130 start-page: 1605 year: 2006 ident: key 2019041002323634100_R16 publication-title: Chest doi: 10.1378/chest.130.5.1605 – year: 2007 ident: key 2019041002323634100_R24 – year: 2007 ident: key 2019041002323634100_R2 |
SSID | ssj0012806 |
Score | 2.030588 |
SecondaryResourceType | review_article |
Snippet | Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed.
The Department of... Purpose. Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed. Summary.... Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed.PURPOSEWorking with... |
SourceID | proquest gale pubmed crossref highwire |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 176 |
SubjectTerms | Biomedical Research - ethics Biomedical Research - standards Ethics Committees, Research - ethics Ethics Committees, Research - standards Human Experimentation - ethics Human Experimentation - standards Human experimentation in medicine Humans Self-experimentation in medicine United States United States Dept. of Health and Human Services - ethics United States Dept. of Health and Human Services - standards |
Title | Working with the institutional review board |
URI | http://www.ajhp.org/content/66/2/176.abstract https://www.ncbi.nlm.nih.gov/pubmed/19139484 https://www.proquest.com/docview/66811914 |
Volume | 66 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZb-jIYY-tu2aUTbHSMVMGWFdl6TLZ1ZQ-jDyn0TUi2TBlpEpaUkP36HfnIl4SOXV5MMEKW9Z0c69y-Q8i72MZlZEzE4kRaBvaGYaYUCZOFzVyRCCdslW3xTZ5diK-Xo8s2ib2qLlnbYf7z1rqS_0EV7gGuvkr2H5BtJoUb8BvwhSsgDNe_wjh4uoMz9crzf2DoH_17oSzFLkLlfMM2W0dpOrQRWA_JkNh5sERC69bd7rxve_BlOJhsmwzQ2lfgM6EYVkt20vO93ggZoT5WgNMjP_rgHKcHCeu4CsFCVLDv2CRo6GpFOWJcRVFXk2L_lCAxvKMWY-zxsq-ueeAp_n61BM0TyZ1BsNXL6wq42FOXIuXpHmP23pesyS_cbDZSaq7huXfJAQcLgvfIwXjyaXLahJh8SBkTUvHlkLuWVx2AmgVVnLL49J2DS_35rjmlf2-fVOeU6UPyIBgYdIzS8ojccfNDchx2fHtCp23B3eqEHtPzlrt8e0juoxuXIl6PSR1MoV7EKIgY3RExiiJGKxF7Qi5OP08_nrHQX4PlyUisWRqVXBUydcZwXlolncwSK1NhfPuqdGSVSLMkUjZyKnag-7NcpIUoVKlik_AoeUp688XcPSc0t0WRypKX0uZCOaFEXsIMoiyKgqtc9cmHevN0HsjnfQ-UmQYjlFeF8c2e98nbZuwSKVduHfXeY6C9qMBMuQnlJLAez2imx9yzFfLUjzyqYdKrazObATxcd0SkT97U4GlQrj5iZuZucbPSUmYVAWKfPENM2wUFqXjxp8lfknvtP_EV6a1_3LjXcI5d26Mgkb8Aetifjw |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Working+with+the+institutional+review+board&rft.jtitle=American+journal+of+health-system+pharmacy&rft.au=Wesley+G.+Byerly&rft.date=2009-01-15&rft.pub=American+Society+of+Health-System+Pharmacists&rft.issn=1079-2082&rft.eissn=1535-2900&rft.volume=66&rft.issue=2&rft.spage=176&rft_id=info:doi/10.2146%2Fajhp070066&rft_id=info%3Apmid%2F19139484&rft.externalDBID=n%2Fa&rft.externalDocID=www66_2_176 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-2082&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-2082&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-2082&client=summon |